Drugs / PTgen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03035370 | Sep 2016 → Apr 2018 | pertussis | DBV Technologies | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PTgen | “Objectives of this study were to evaluate safety and capacity of a recombinant pertussis toxin (PTgen) -coated Viaskin® epicutaneous patch to recall memory responses in healthy adults.” PMID 32896653 ↗ Sep 2020 |
| Route | Other | “administered via the cutaneous route” NCT03035370 ↗ |